Pediatric nephrology (Berlin, Germany)
Tiopronin safety in cystinuria: first real-world pharmacovigilance analysis using the FDA Adverse Event Reporting System (FAERS): an EAU YAU and Endourology sections review.
Rifat Burak Ergül, Ismail Taha Gürlek, M Fırat Özervarlı, Şeyda Gül Özcan, Amelia Pietropaolo, Arman Tsaturyan, Patrick Juliebø-Jones, Lazaros Tzelves, Tarik Emre Şener, M İrfan Dönmez, Tayfun Oktar, Bhaskar Somani, Tzevat Tefik
Published: 202510.1007/s00467-025-07043-2
Abstract
BACKGROUND: Cystinuria is a rare genetic disorder that causes recurrent cystine stones and significant morbidity, particularly in children. Tiopronin, the main pharmacologic therapy when conservative measures fail, reduces cystine precipitation and e…
Preview only. Read the full abstract at the source